Interestingly, there was no significant difference in prostate cancer development between non-mutated HBOC families and HBOC families that harbored mutations in BRCA, PALB2, RAD51C, TP53 and MUTYH genes. This evidence concerns the gene PALB2 and prostate carcinoma.